Cancer's escape routes are getting named, one pathway at a time
Melanoma cells lose their interferon response and dodge T cells, prostate tumours lean on YAP and TAZ, and TEAD blockers that reach the brain extend survival in glioblastoma models.
- In a preprint, AHR deficiency in melanoma cells leads to delayed resistance to CD8 adoptive T-cell therapy, with progressive loss of interferon gamma responsiveness and MHC expression under chronic stimulation. Self-reported m:…3962
- In a preprint, decitabine treatment partially restores MHC expression in AHR-deficient melanoma cells, and CD4 cell therapy effectively eradicates AHR-deficient melanomas. Self-reported m:…3962
- In a preprint on triple-negative breast cancer, baseline TNF-alpha/NF-kappaB signalling in cytotoxic T/NK and B cells is associated with not reaching a complete response, while a higher proportion of CX3CR1-expressing CD4 cells predicts a complete response with an AUC of 0.949 and a higher switched-memory B-cell CD38 balance predicts it with an AUC of 0.825. Self-reported m:…6034
- In preprints, enzalutamide-resistant prostate cancer cells show activation of the YAP-1/TAZ-TEAD complex, and the TEAD inhibitor VT104 reaches the brain with a brain-to-plasma ratio above 150% and extends overall survival in recurrent glioblastoma models when combined with radiotherapy and temozolomide. Self-reported m:…1307 m:…8838
Melanoma learns to hide
In a preprint on melanoma, researchers found that the aryl hydrocarbon receptor, AHR, is what keeps tumour cells responsive to interferon gamma, the signal that helps T cells recognise them. When melanoma cells lose AHR, they progressively lose interferon gamma responsiveness and MHC expression under chronic stimulation, which is how a tumour stops being visible to the immune system, and the result is delayed resistance to CD8 adoptive T-cell therapy. m:…3962
The resistance is not permanent, at least in the experiments. Decitabine treatment partially restores MHC expression in AHR-deficient cells, which points to epigenetic regulation of the resistance, and CD4 cell therapy effectively eradicates AHR-deficient melanomas. The paper's message is that the escape has a mechanism, and a mechanism can be worked around. m:…3962
What predicts a full response
A preprint on early triple-negative breast cancer followed the immune system through treatment, measuring circulating immune cells in patients receiving pembrolizumab. Baseline TNF-alpha/NF-kappaB signalling in cytotoxic T/NK and B cells was associated with not reaching a pathological complete response, the outcome where no tumour remains by surgery. Two other signals pointed the other way: a higher proportion of CX3CR1-expressing cells within the CD4 memory/activation-like compartment was associated with a complete response, with an AUC of 0.949, and a higher pre-surgery switched-memory B-cell CD38 balance was also higher in patients who reached a complete response, with an AUC of 0.825. m:…6034
The same pathway, twice
In prostate cancer, the escape route has a name: YAP1/TAZ-TEAD. A preprint finds that enzalutamide-resistant prostate cancer cells show marked activation and nuclear enrichment of the YAP-1/TAZ-TEAD complex, and that increased YAP-1/WWTR1 (Taz) expression is a negative predictor of therapeutic response in patients. Disrupting the YAP-1/TAZ-TEAD interface with CA3 inhibits migration, invasion and colony formation in both AR-dependent and AR-independent prostate cancer cell lines, which makes the axis a target rather than just a marker. m:…1307
The same axis shows up in the brain. A preprint on recurrent glioblastoma tested TEAD palmitoylation inhibitors VT103 and VT104, which inhibit tumour proliferation and migration in vitro while downregulating TEAD-target expression. VT104 reaches the brain, achieving a brain-to-plasma ratio above 150% in PDX mice, and combined with radiotherapy and temozolomide it significantly extends overall survival in recurrent glioblastoma models. The drug also potentiates temozolomide-dependent genotoxic stress and works with radiotherapy and temozolomide to abolish TEAD activity. m:…8838
Why naming the move matters
The pattern across the four papers is the same: resistance is not a mystery, it is a mechanism, and mechanisms have addresses. AHR loss, YAP and TAZ activation, the immune signals that predict a complete response, each one is a place to aim the next experiment. None of these is a treatment yet. All four are preprints, and the glioblastoma and prostate results come from models and cell lines, not patients. But a field that can name the escape route is a field that can design the next trial around it. m:…3962
The breast cancer paper's two predictors are worth a second look. A CX3CR1 signal with an AUC of 0.949 is a strong predictor by the standards of this kind of work, and the B-cell signal at 0.825 is weaker but points at a different part of the immune system, which is why the paper reports both rather than picking a winner. A strong signal and a weaker one, from different cell types, is more useful than either alone: it suggests the response is written across the immune system, not in a single cell. m:…6034
What is still unresolved
- Whether the AHR mechanism operates the same way in patients as in the experiments
- Whether the triple-negative breast cancer immune signals predict response in larger cohorts
- Whether TEAD inhibitors are safe enough for human trials
- Whether targeting YAP/TAZ-TEAD works outside the models tested
Provenance by Synorb. Every claim links to its source. This story was written by an agent from the Manifests listed below. Read the methodology and limitations, or send a correction.
Free to reuse, including commercially. Credit “Hanging Context, with provenance by Synorb” and link to this story. Keep the cited Manifest ids. Reuse terms v1.